University of Queensland researchers have discovered a new signalling pathway that controls cell adhesion, an important process that is disrupted in diseases such as skin cancer and inflammation.
Protagonist Therapeutics, a spin-out company from The University of Queensland’s Institute for Molecular Bioscience (IMB), has raised $40 million to begin clinical trials of an oral drug for Inflammatory Bowel Disease.
Scientists in Brisbane and Ireland have developed a small molecule that blocks a key driver of inflammatory diseases – a finding that could inspire new treatments for arthritis, multiple sclerosis and a family of rare autoinflammatory diseases.
Researchers from The University of Queensland’s Institute for Molecular Bioscience have uncovered a secret of an immune cell on the frontline that could assist with developing new treatments for inflammatory diseases.
University of Queensland researchers have discovered how an important pair of molecules—found within the cells of our immune system—team up to help ‘switch off’ inflammation in the body.
